Moody Aldrich Partners LLC Fate Therapeutics Inc Transaction History

Moody Aldrich Partners LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 18, 2022	BUY	$21.04 - $36.06 $1.52 Million - $2.61 Million	72,304 New	72,304 $1.62 Million
Q4 2018 Feb 12, 2019	SELL	$11.48 - $16.98 $1.14 Million - $1.68 Million	-98,993 Closed	0 $0
Q3 2018 Oct 31, 2018	BUY	$8.75 - $16.29 $136,622 - $254,352	15,614 Added 18.73%	98,993 $1.61 Million
Q2 2018 Aug 13, 2018	BUY	$9.16 - $13.48 $763,751 - $1.12 Million	83,379 New	83,379 $946,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $235M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Aldrich Partners LLC with notifications on news.